论文信息 - First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs). - 字舞流文

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

M. Konopleva | A. Chanan-Khan | Dajun Yang | M. Davids | Y. Zhai | C. Tam | D. Brander | H. Prince | D. Rizzieri | M. Lasica | S. Ailawadhi | Zhiyan Liang | Bo Huang | Zi Chen | B. Mudenda | C. Yannakou | Z. He | Mohammad Ahmad | M. Lu | Mingyu Li